Dendreon Corporation  

(Public, OTCMKTS:DNDNQ)   Watch this stock  
Find more results for Andrew Pacheco�
0.100
+0.007 (7.53%)
After Hours: 0.101 0.000 (0.00%)
Dec 19, 4:33PM EST  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.09 - 0.11
52 week 0.07 - 3.52
Open 0.10
Vol / Avg. 1.78M/9.62M
Mkt cap 15.87M
P/E     -
Div/yield     -
EPS -1.06
Shares 158.72M
Beta 2.34
Inst. own 33%
Mar 2, 2015
Q4 2014 Dendreon Corp Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 10, 2014
Q3 2014 Dendreon Corp Earnings Release
  

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -30.18% -104.60%
Operating margin -11.93% -85.65%
EBITD margin - -54.78%
Return on average assets -25.12% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -

Address

SUITE 3200, 1301 2ND AVE.
SEATTLE, WA 98101
United States - Map
+1-206-2197815 (Phone)
+1-302-6555049 (Fax)

Website links

Description

Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).

Officers and directors

Douglas G. Watson Chairman of the Board
Age: 69
W. Thomas Amick President, Chief Executive Officer, Director
Age: 71
Gregory R. Cox Interim Chief Financial Officer, Vice President, Treasurer
Age: 48
William Monteith Executive Vice President - Technical Operations
Age: 56
Lindsay Rocco Executive Vice President - Corporate Communications
Age: 35
Andrew S. Sandler M.D. Executive Vice President, Chief Medical Officer
Age: 49
William Jenkinson Chief Marketing Officer, Vice President
Age: 43
Robert L. Crotty Vice President, Interim General Counsel and Secretary
Age: 40
Karen E. Brophy Vice President, Head of Human Resources
Age: 51
Silvio Pacheco Vice President, Chief Customer Officer
Age: 48